Document Detail

Embedding 'Speaking Up' into Systems for Safe Healthcare Product Development and Marketing Surveillance.
MedLine Citation:
PMID:  22339507     Owner:  NLM     Status:  Publisher    
Robust, active cooperation, and effective, open communication between all stakeholders is essential for ensuring regulatory compliance and healthcare product safety; avoiding the necessity for whistle-blowing; and, most essentially, meeting the transparency requirements of public trust. The focus here is on what can be done within a healthcare product organization (HPO) to achieve actionable, sustainable policies and practices such as leadership, management, and supervision role-modelling of best practice; ongoing process review and improvements in every department; protection of those who report concerns through robust policies endorsed at Board level throughout an organization to eliminate the fear of retaliation; training in open, non-defensive team-working principles; and mediation structure and process for resolution of differences of opinion or interpretation of contradictory and volatile data. Based on analyses of other safety systems, workplace silence and interpersonal breakdowns are warning signs of defective systems underlying poor compliance and compromising safety. Remedying the situation requires attention to the root causes underlying such symptoms of dysfunction, especially the human factor, i.e. those factors that influence human performance. It is essential that leadership and management listen to employees' concerns about systems and processes, assess them impartially and reward contributions that improve safety. Fundamentally, the safety, transparency, and trustworthiness of HPOs, both commercial and regulatory, can be judged by the extent of the freedom of their staff to 'speak up' when the time is right. This, in turn, consolidates the trust of external stakeholders in the safety of a system and its products. The promotion of 'speaking up' in an organization provides an important safeguard against the risk of poor compliance and the undermining of societal confidence in the safety of healthcare products.
Brian Edwards; Bruce Hugman; Mary Tobin; Matthew Whalen
Related Documents :
24825697 - Supporting knowledge discovery in medicine.
15902447 - Corporate environmental policy statements in mainland china: to what extent do they con...
16784947 - Accuracy of radiographers red dot or triage of accident and emergency radiographs in cl...
16891857 - The case for case reports: avoiding statistical seduction.
21279127 - Management of common postpartum problems.
21438647 - A systematic overview of the medicinal importance of sanguivorous leeches.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-17
Journal Detail:
Title:  Drug safety : an international journal of medical toxicology and drug experience     Volume:  -     ISSN:  0114-5916     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
NDA Regulatory Science Ltd, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk Minimization Activities of Centrally Authorized Products in the EU: A Descriptive Study.
Next Document:  The problem just keeps getting bigger.